Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Seoul says sorry after unapproved drone flights into North Korea - 2Language Learning Applications for Voyagers
- 3Dominating Online Entertainment Showcasing: 7 Hints for Organizations
- 4Most loved Road Food: Which One Prevails upon You?
- 5NASA wants to build a base on the Moon by the 2030s – how and why it plans to build up to a long-term lunar presence
- Reactions as Artemis II astronauts lift off on historic lunar mission
- The Golden Globes is happening Sunday: Who's nominated, who's hosting and how to watch
- New materials, old physics – the science behind how your winter jacket keeps you warm
- First Alert: Light snow through this evening
- Exploring Being a parent: A Survey of \Bits of knowledge and Guidance for Guardians\ Nurturing Book
- Free Fuel Giveaway Sparks Traffic Mayhem Before Police Shut It Down
- Iran war triggering Easter staycation boom
- The Best Games On the planet
- Blue Origin's next space tourism flight will break new ground for people with disabilities
